Cambridge, United States
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company established in 2016 and based in the United States. It aims to enhance the lives of patients who suffer from genetically defined diseases, especially those in urgent need, with a primary focus on rare diseases.
Positioned at the intersection of biotechnology and health care, Fulcrum Therapeutics is making strides in the health and wellness industry by leveraging cutting-edge research to address significant gaps in medical treatments. The company's focus on untreated or inadequately treated conditions has the potential to disrupt traditional therapeutic approaches.
In January 2023, Fulcrum Therapeutics secured a $125.00M post-IPO equity investment. This significant capital injection underpins its mission to advance its clinical programs and broaden its research scope.
The company's continuous commitment to innovation and its robust early-stage performance present a compelling opportunity for investors looking to support transformative solutions in the healthcare sector.
